613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors
Year: 2024
Type: article
Source: Annals of Oncology
Institutions: Centre Léon Bérard, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of South Florida, Moffitt Cancer Center, University of California, Los Angeles, The University of Western Australia, Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Hospital Clínico Universitario de Valencia, Sarah Cannon, Sidney Kimmel Cancer Center, City Of Hope National Medical Center, City of Hope, The University of Sydney, Melanoma Institute Australia, Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4402560115